Tags : G1 Therapeutics

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 01 – 05, 2021)

Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata Published: Mar 5, 2021 | Tags: Eli Lilly and Incyte, Report, Results, Olumiant (baricitinib), P-III, BRAVE-AA2, Study, Severe, Alopecia Areata Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan Published: Mar 5, 2021 | Tags: […]Read More

Pharma

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the

Shots: On Feb 12, 2021, the US FDA has approved Cosela to decrease the incidence of CT induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC The launch is supported by the “One Patient Support Program” which is designed to provide access and affordability solutions to eligible patients […]Read More

Regulatory

G1 Therapeutics’ Cosela (trilaciclib) Receives US FDA’s Approval as the

Shots: The approval is based on three clinical trials involves assessing Trilaciclib +carboplatin/etoposide (+/- atezolizumab) and topotecan CT regimens in patients with ES-SCLC. 90% of all patients with ES-SCLC will receive at least one of these regimens The result show reductions in the incidence and duration of severe neutropenia, positive impact on RBC transfusions and […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Aug 17 -21 2020)

1. BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia Published: Aug 20, 2020 | Tags:  BioMarin, Reports, NDA, Submission, US, FDA, Vosoritide, Children, Achondroplasia 2. Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China Published: Aug 20, 2020 | Tags:  Junshi, Impact, Establish, Joint Venture, […]Read More

Pharma

G1 Therapeutics and Boehringer Ingelheim Collaborate to Co-Promote Trilaciclib for

Shots: Boehringer to receive payments to cover start-up expenses and pre-approval initiatives for a successful commercial launch. Additionally, it receives mid-twenties percentage of net sales in the 1st yr. of commercialization, which decreases to a low double-digit/high single-digit percentage in the 2nd and 3rd year respectively G1 will book revenue in the selective territories and […]Read More